AVGO:NASDAQ
Broadcom Inc.
Data as of 2026-03-09 - not real-time
$330.45
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Broadcom (AVGO) is trading at $330.45, just above its 20‑day SMA of $329.60 but below the 50‑day SMA of $334.32, indicating a modest short‑term edge while the broader trend remains neutral (RSI 51, MACD histogram +0.52). Volume is increasing, and the MACD line has crossed above its signal, a bullish technical signal that aligns with the recent double‑beat earnings and the company’s bold AI chip sales forecast of $100B+ by 2027. Fundamentally, the stock carries a high trailing PE of 69.4x versus the semiconductor industry average of 36.2x, suggesting it is currently overvalued, yet a forward PE of 19.1x and a strong EPS outlook (forward EPS $17.31) point to significant growth potential. The balance sheet shows $11.1B cash offset by $40.5B debt, yielding a high debt‑to‑equity of 166%, but robust operating cash flow ($29.7B) and free cash flow ($25.4B) support dividend sustainability and future investment. Dividend yield sits at 0.79% with a payout ratio under 50%, which, combined with a solid ROE of 33%, suggests the dividend is defensible despite leverage. Analyst consensus is heavily bullish (strong‑buy, median target $475), implying a potential upside of roughly 40% from current levels, though the DCF fair value of $141 highlights a stark valuation gap.
Overall, the stock presents a compelling growth story anchored by AI and infrastructure software tailwinds, but investors must weigh the high valuation, elevated beta (≈1.7), and debt load against the strong cash generation and market positioning. The near‑term price action may test the $307 support and $352 resistance zones, while the medium‑to‑long‑term narrative remains anchored in expanding AI‑driven demand and disciplined capital returns.
Overall, the stock presents a compelling growth story anchored by AI and infrastructure software tailwinds, but investors must weigh the high valuation, elevated beta (≈1.7), and debt load against the strong cash generation and market positioning. The near‑term price action may test the $307 support and $352 resistance zones, while the medium‑to‑long‑term narrative remains anchored in expanding AI‑driven demand and disciplined capital returns.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 7/10
Key Factors
- Bullish MACD crossover with rising volume
- Price testing near $307 support and $352 resistance
- Elevated valuation relative to peers
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- Strong AI chip sales outlook and double‑beat earnings
- Forward PE of 19.1x indicating attractive growth pricing
- Analyst consensus strong‑buy with median target $475
Long Term
> 3 yearsbuy
Conviction: 8/10
Key Factors
- Sustained cash flow supporting dividend and debt repayment
- Strategic positioning in data‑center and AI infrastructure
- Long‑term growth trajectory despite current overvaluation
Key Metrics & Analysis
Financial Health
Revenue Growth16.40%
Profit Margin36.57%
P/E Ratio69.4
ROE33.37%
ROA10.62%
Debt/Equity166.03
P/B Ratio5.6
Op. Cash Flow$29.7B
Free Cash Flow$25.4B
Industry P/E36.2
Technical Analysis
TrendNeutral
RSI51.0
Support$307.20
Resistance$352.34
MA 20$329.60
MA 50$334.32
MA 200$320.70
MACDBullish
VolumeIncreasing
Fear & Greed Index68.77
Valuation
Fair Value$141.01
Target Price$467.62
Upside/Downside41.51%
GradeOvervalued
TypeGrowth
Dividend Yield0.79%
Risk Assessment
Beta1.70
Volatility37.72%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.